Clinical Trial Update: Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating closure of membranous ventricular septal defects with the AMPLATZER Membranous VSD Occluder by Abbott Medical Devices has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Ventricular Septal Defect

Drugs mentioned

• AMPLATZER Membranous VSD Occluder

Snippet

Sponsor: Abbott Medical Devices | Conditions: Membranous Ventricular Septal Defects | Phase 1 | Status: COMPLETED